---
title: "FOLD.US (FOLD.US) — Related News"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/FOLD.US/news.md"
symbol: "FOLD.US"
name: "FOLD.US"
parent: "https://longbridge.com/en/quote/FOLD.US.md"
datetime: "2026-03-14T02:29:03.511Z"
locales:
  - [en](https://longbridge.com/en/quote/FOLD.US/news.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/FOLD.US/news.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/FOLD.US/news.md)
---

> Supported Languages: [简体中文](https://longbridge.com/zh-CN/quote/FOLD.US/news.md) | [繁體中文](https://longbridge.com/zh-HK/quote/FOLD.US/news.md)


# FOLD.US (FOLD.US) — Related News

### [BioMarin Pharmaceutical Highlights Growth Plan, VOXZOGO Milestones, and Amicus Deal at Conference](https://longbridge.com/en/news/279015256.md)
*2026-03-13T09:12:04.000Z*
> BioMarin Pharmaceutical executives presented a growth strategy focused on innovation and value commitment during a recen

### [BioMarin Pharmaceutical touts 13% 2025 revenue growth, Amicus deal, and 2026 pipeline catalysts at Barclays event](https://longbridge.com/en/news/279007407.md)
*2026-03-13T08:22:00.000Z*
> BioMarin Pharmaceutical executives announced a projected 13% revenue growth for 2025, driven by strong performance in it

### [Fold repaid $66.3 million in debt, releasing 521 Bitcoin collateral assets](https://longbridge.com/en/news/277528550.md)
*2026-03-02T22:39:16.000Z*
> [Fold repaid $66.3 million in debt, releasing 521 Bitcoin collateral assets] According to Golden Finance, Nasdaq-listed 

### [Vanguard Group Inc. Buys 126,441 Shares of Amicus Therapeutics, Inc. $FOLD](https://longbridge.com/en/news/277466601.md)
*2026-03-02T12:51:28.000Z*
> Vanguard Group Inc. increased its stake in Amicus Therapeutics, Inc. (NASDAQ:FOLD) by 0.4% in Q3, acquiring an additiona

### [BioMarin pulls gene therapy Roctavian off the market](https://longbridge.com/en/news/276771733.md)
*2026-02-24T17:42:50.000Z*
> BioMarin has decided to withdraw its hemophilia A gene therapy, Roctavian, from the market after failing to find a buyer

### [Legal Challenges Loom Over Amicus–BioMarin Merger, Raising Execution and Shareholder Risks](https://longbridge.com/en/news/276528811.md)
*2026-02-22T06:05:44.000Z*
> Amicus Therapeutics (FOLD) faces legal challenges regarding its merger with BioMarin, which could lead to costly litigat

### [Amicus Q4 revenue beats estimates](https://longbridge.com/en/news/276485847.md)
*2026-02-20T21:10:17.000Z*
### [Amicus Therap | 10-K: FY2025 Revenue Beats Estimate at USD 634.21 M](https://longbridge.com/en/news/276485511.md)
*2026-02-20T21:07:45.000Z*
### [Amicus Therapeutics Q4 Revenue USD 185.2 Million Vs. IBES Estimate USD 180.7 Million](https://longbridge.com/en/news/276484917.md)
*2026-02-20T21:01:46.000Z*